Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it

Steven P. Rowe; Andrew F. Voter; Rudolf A. Werner; Katherine A. Zukotynski; Martin G. Pomper; Michael A. Gorin; Lilja B. Solnes

Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it

Steven P. Rowe, Andrew F. Voter, Rudolf A. Werner, Katherine A. Zukotynski, Martin G. Pomper, Michael A. Gorin, Lilja B. Solnes

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Prostate cancer is the second most common malignancy in men with more than one million new cases diagnosed worldwide each year.1 Accurate diagnostic imaging for staging and re-staging of men with prostate cancer is paramount and this need has recently been at least partly addressed by the widespread adoption of center, registration trials, OSPREY (patient population: highrisk primary staging) and CONDOR (patient population: biochemical recurrence). In this manuscript, we will (1) review key findings from the OSPREY and CONDOR trials, (2) discuss the clinical acquisition protocol we use for 18F-DCFPyL PET scanning, (3) present information on important pearls and pitfalls, (4) provide an overview of the PSMA reporting and data system (PSMA-RADS) interpretive framework, and (5) posit important future directions for research in PSMA PET.

Original language	English
Pages (from-to)	11432-11437
Number of pages	6
Journal	Canadian Journal of Urology
Volume	30
Issue number	1
State	Published - 2023

Keywords

CONDOR
OSPREY
PSMA
prostate cancer
prostate-specific membrane antigen

Cite this

@article{e36a045633ab4973b7c4b577bf7dafc4,

title = "Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it",

abstract = "Prostate cancer is the second most common malignancy in men with more than one million new cases diagnosed worldwide each year.1 Accurate diagnostic imaging for staging and re-staging of men with prostate cancer is paramount and this need has recently been at least partly addressed by the widespread adoption of center, registration trials, OSPREY (patient population: highrisk primary staging) and CONDOR (patient population: biochemical recurrence). In this manuscript, we will (1) review key findings from the OSPREY and CONDOR trials, (2) discuss the clinical acquisition protocol we use for 18F-DCFPyL PET scanning, (3) present information on important pearls and pitfalls, (4) provide an overview of the PSMA reporting and data system (PSMA-RADS) interpretive framework, and (5) posit important future directions for research in PSMA PET.",

keywords = "CONDOR, OSPREY, PSMA, prostate cancer, prostate-specific membrane antigen",

author = "Rowe, {Steven P.} and Voter, {Andrew F.} and Werner, {Rudolf A.} and Zukotynski, {Katherine A.} and Pomper, {Martin G.} and Gorin, {Michael A.} and Solnes, {Lilja B.}",

note = "Publisher Copyright: {\textcopyright} {\textcopyright} The Canadian Journal of Urology{\texttrademark}",

year = "2023",

language = "English",

volume = "30",

pages = "11432--11437",

journal = "Canadian Journal of Urology",

issn = "1195-9479",

publisher = "Canadian Journal of Urology",

number = "1",

}

TY - JOUR

T1 - Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT

T2 - How we do it

AU - Rowe, Steven P.

AU - Voter, Andrew F.

AU - Werner, Rudolf A.

AU - Zukotynski, Katherine A.

AU - Pomper, Martin G.

AU - Gorin, Michael A.

AU - Solnes, Lilja B.

N1 - Publisher Copyright: © © The Canadian Journal of Urology™

PY - 2023

Y1 - 2023

N2 - Prostate cancer is the second most common malignancy in men with more than one million new cases diagnosed worldwide each year.1 Accurate diagnostic imaging for staging and re-staging of men with prostate cancer is paramount and this need has recently been at least partly addressed by the widespread adoption of center, registration trials, OSPREY (patient population: highrisk primary staging) and CONDOR (patient population: biochemical recurrence). In this manuscript, we will (1) review key findings from the OSPREY and CONDOR trials, (2) discuss the clinical acquisition protocol we use for 18F-DCFPyL PET scanning, (3) present information on important pearls and pitfalls, (4) provide an overview of the PSMA reporting and data system (PSMA-RADS) interpretive framework, and (5) posit important future directions for research in PSMA PET.

AB - Prostate cancer is the second most common malignancy in men with more than one million new cases diagnosed worldwide each year.1 Accurate diagnostic imaging for staging and re-staging of men with prostate cancer is paramount and this need has recently been at least partly addressed by the widespread adoption of center, registration trials, OSPREY (patient population: highrisk primary staging) and CONDOR (patient population: biochemical recurrence). In this manuscript, we will (1) review key findings from the OSPREY and CONDOR trials, (2) discuss the clinical acquisition protocol we use for 18F-DCFPyL PET scanning, (3) present information on important pearls and pitfalls, (4) provide an overview of the PSMA reporting and data system (PSMA-RADS) interpretive framework, and (5) posit important future directions for research in PSMA PET.

KW - CONDOR

KW - OSPREY

KW - PSMA

KW - prostate cancer

KW - prostate-specific membrane antigen

UR - http://www.scopus.com/inward/record.url?scp=85148113123&partnerID=8YFLogxK

M3 - Article

C2 - 36779950

AN - SCOPUS:85148113123

SN - 1195-9479

VL - 30

SP - 11432

EP - 11437

JO - Canadian Journal of Urology

JF - Canadian Journal of Urology

IS - 1

ER -

Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it

Abstract

Keywords

Fingerprint

Cite this